Population pharmacokinetics and pharmacodynamics of the artesunate–mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children

[1]  M. Karlsson,et al.  Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar , 2018, Malaria Journal.

[2]  M. Karlsson,et al.  Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia , 2017, The AAPS Journal.

[3]  A. Mtoro,et al.  Comparison of artesunate–mefloquine and artemether–lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial , 2016, The Lancet. Infectious Diseases.

[4]  R. Upton,et al.  Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria. , 2015, The Journal of antimicrobial chemotherapy.

[5]  B. Sharma,et al.  Population pharmacokinetics of mefloquine, administered as a fixed-dose combination of artesunate-mefloquine in Indian patients for the treatment of acute uncomplicated Plasmodium falciparum malaria , 2014, Malaria Journal.

[6]  A. Dash,et al.  Safety, efficacy and population pharmacokinetics of fixed-dose combination of artesunate-mefloquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in India. , 2013, Journal of vector borne diseases.

[7]  S. Pai,et al.  Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  D. Ménard,et al.  Therapeutic efficacy of fixed dose artesunate-mefloquine for the treatment of acute, uncomplicated Plasmodium falciparum malaria in Kampong Speu, Cambodia , 2013, Malaria Journal.

[9]  Beesan Tan,et al.  Effects of Body Size and Gender on the Population Pharmacokinetics of Artesunate and Its Active Metabolite Dihydroartemisinin in Pediatric Malaria Patients , 2013, Antimicrobial Agents and Chemotherapy.

[10]  Nick Holford,et al.  A pharmacokinetic standard for babies and adults. , 2013, Journal of pharmaceutical sciences.

[11]  T. Buclin,et al.  Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients , 2013, Malaria Journal.

[12]  S. Wells,et al.  The story of artesunate–mefloquine (ASMQ), innovative partnerships in drug development: case study , 2013, Malaria Journal.

[13]  P. Marchesini,et al.  Effect of artesunate-mefloquine fixed-dose combination in malaria transmission in amazon basin communities , 2012, Malaria Journal.

[14]  C. A. Morris,et al.  Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration , 2011, Malaria Journal.

[15]  L. Decosterd,et al.  Residual antimalarial concentrations before treatment in patients with malaria from Cambodia: indication of drug pressure. , 2010, The Journal of infectious diseases.

[16]  P. Olliaro,et al.  New Fixed-Dose Artesunate-Mefloquine Formulation against Multidrug-Resistant Plasmodium falciparum in Adults: a Comparative Phase IIb Safety and Pharmacokinetic Study with Standard-Dose Nonfixed Artesunate plus Mefloquine , 2010, Antimicrobial Agents and Chemotherapy.

[17]  Beesan Tan,et al.  Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects , 2009, Malaria Journal.

[18]  T. Buclin,et al.  Residual Antimalarials in Malaria Patients from Tanzania – Implications on Drug Efficacy Assessment and Spread of Parasite Resistance , 2009, PloS one.

[19]  J. Simpson,et al.  Population pharmacokinetics of artesunate and amodiaquine in African children , 2009, Malaria Journal.

[20]  L. Slutsker,et al.  Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria , 2009, Malaria Journal.

[21]  J. Keiser,et al.  A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[22]  Mats O. Karlsson,et al.  Likelihood based approaches to handling data below the quantification limit using NONMEM VI , 2008, Journal of Pharmacokinetics and Pharmacodynamics.

[23]  F. Nosten,et al.  Population Pharmacokinetic Assessment of a New Regimen of Mefloquine Used in Combination Treatment of Uncomplicated Falciparum Malaria , 2006, Antimicrobial Agents and Chemotherapy.

[24]  K. Rieckmann,et al.  Fatty food does not alter blood mefloquine concentrations in the treatment of falciparum malaria. , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[25]  E. Niclas Jonsson,et al.  Erratum to "PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM" [Comput. Methods Prog. Biomedicine 79 (2005) 241-257] , 2005, Comput. Methods Programs Biomed..

[26]  E. Niclas Jonsson,et al.  PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM , 2005, Comput. Methods Programs Biomed..

[27]  S. Krudsood,et al.  Artesunate and mefloquine given simultaneously for three days via a prepacked blister is equally effective and tolerated as a standard sequential treatment of uncomplicated acute Plasmodium falciparum malaria: randomized, double-blind study in Thailand. , 2002, The American journal of tropical medicine and hygiene.

[28]  M. Pirmohamed,et al.  Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[29]  R. Price,et al.  Population pharmacokinetics of mefloquine in patients with acute falciparum malaria , 1999, Clinical pharmacology and therapeutics.

[30]  R. Price,et al.  Pharmacokinetics of Mefloquine Combined with Artesunate in Children with Acute Falciparum Malaria , 1999, Antimicrobial Agents and Chemotherapy.

[31]  N. White,et al.  Assessment of the pharmacodynamic properties of antimalarial drugs in vivo , 1997, Antimicrobial agents and chemotherapy.

[32]  R. Price,et al.  Mefloquine in infants and young children. , 1996, Annals of tropical paediatrics.

[33]  Nicholas H. G. Holford,et al.  A Size Standard for Pharmacokinetics , 1996, Clinical pharmacokinetics.

[34]  Lewis B. Sheiner,et al.  Some suggestions for measuring predictive performance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[35]  G. Saunders,et al.  The treatment of malaria. , 1947, Missouri medicine.

[36]  Organización Mundial de la Salud.  Guidelines for the treatment of malaria , 2010 .

[37]  Ss Beal,et al.  NONMEM User’s Guides. (1989–2009) , 2009 .

[38]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.

[39]  L. Loutan,et al.  Pharmacokinetics of artemisinin and artesunate after oral administration in healthy volunteers. , 1997, The American journal of tropical medicine and hygiene.

[40]  J. Barré,et al.  Food increases the bioavailability of mefloquine , 1997, European Journal of Clinical Pharmacology.

[41]  R. Price,et al.  Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. , 1995, Bulletin of the World Health Organization.